May cause fat redistribution. Patients may develop immune reconstitution syndrome resulting in occurrence of inflammatory response to indolent or residual opportunistic infection. Increases in total cholesterol and triglycerides reported. Changes in glucose tolerance, hyperglycemia, exacerbation of diabetes, DKA, and new-onset diabetes mellitus reported in patients receiving protease inhibitors. Use with caution in hemophilia A or B. May cause hepatitis and/or exacerbate pre-existing hepatic dysfunction (use with caution in underlying hepatic disease, such as hepatitis B or C, cirrhosis, or unspecified hepatic impairment). Use with caution in increased triglycerides (pancreatitis observed). Use with caution in patients taking strong CYP3A4 inhibitors, moderate or strong CYP3A4 inducers and major CYP3A4 substrates. Contraindicated with certain CYP3A4 substrates and inducers. Contraindicated with ergot derivatives, midazolam, pimozide, and triazolam. Avoid concurrent use with St. John’s wort. Dyslipidemia common (use caution with clozapine, olanzapine, and quetiapine). Diarrhea common (use caution with lithium, valproic acid, and SSRIs). Increased LFTs common (use caution with olanzapine and valproic acid). May cause hyperglycemia (use caution with clozapine and olanzapine). May cause thrombocytopenia (use caution with valproic acid). Carbamazepine, phenytoin, and phenobarbital may decrease levels of lopinavir. Ritonavir may increase levels of zolpidem. Solution contains ethanol (use caution with disulfiram).